The experimental support for this entirely novel treatment approach and cancer growth control originates from our published data which indicate that absence of TNFR2/p75 in the host tissue of p75 knockout (KO) mice inhibited >50% growth of implanted Lewis lung carcinoma 1 (LLC) cells and metastatic B16 mouse melanoma cells (B16). This evidence concerns the gene TNFRSF1B and cancer.